Contact Lenses

FDA policy change on classification of noncorrective lenses

The US FDA has relaxed its policy on the regulation of noncorrective contact lenses (also called zero-powered, plano, decorative or cosmetic lenses), while at the same time acknowledging that these lenses can cause a variety of eye injuries1,2. Up until recently, the FDA's policy was to regulate such contact lenses as medical devices, but now the agency has decided that they are cosmetics under the Federal Food, Drug, and CosmeticAct because they are `articles... applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance'. In an April 2003 Federal Register notice, the FDA supports its new position by stating that `The fact that contact lenses are `devices' in the colloquial sense does not preclude cosmetic status under the act... Moreover, the fact that a product is intended to come into contact with the eye does not make it ineligible for cosmetic regulation... Provided they are not marketed with claims... that they effect physical or physiological change, decorative contact lenses are properly regulated as cosmetics under the act.'

According to the FDA, although only corrective contact lenses are required to comply with medical device regulations, sponsors may voluntarily include noncorrective contact lenses in their pre-market notifications [510(k)] as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.